Literature DB >> 30150207

A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.

Zhuting Hu1, Annabelle J Anandappa1,2, Jing Sun1, Jintaek Kim1, Donna E Leet1,2, David J Bozym1,2, Christina Chen1, Louise Williams3, Sachet A Shukla1,3,4, Wandi Zhang1, Diana Tabbaa3, Scott Steelman3, Oriol Olive1, Kenneth J Livak4, Hiroyuki Kishi5, Atsushi Muraguchi5, Indira Guleria6, Jonathan Stevens6, William J Lane2,6, Ute E Burkhardt1, Edward F Fritsch1,3, Donna Neuberg7, Patrick A Ott1,2,8, Derin B Keskin1,2,3,8, Nir Hacohen2,3,9, Catherine J Wu1,2,3,8.   

Abstract

Recent studies have highlighted the promise of targeting tumor neoantigens to generate potent antitumor immune responses and provide strong motivation for improving our understanding of antigen-T-cell receptor (TCR) interactions. Advances in single-cell sequencing technologies have opened the door for detailed investigation of the TCR repertoire, providing paired information from TCRα and TCRβ, which together determine specificity. However, a need remains for efficient methods to assess the specificity of discovered TCRs. We developed a streamlined approach for matching TCR sequences with cognate antigen through on-demand cloning and expression of TCRs and screening against candidate antigens. Here, we first demonstrate the system's capacity to identify viral-antigen-specific TCRs and compare the functional avidity of TCRs specific for a given antigen target. We then apply this system to identify neoantigen-specific TCR sequences from patients with melanoma treated with personalized neoantigen vaccines and characterize functional avidity of neoantigen-specific TCRs. Furthermore, we use a neoantigen-prediction pipeline to show that an insertion-deletion mutation in a putative chronic lymphocytic leukemia (CLL) driver gives rise to an immunogenic neoantigen mut-MGA, and use this approach to identify the mut-MGA-specific TCR sequence. This approach provides a means to identify and express TCRs, and then rapidly assess antigen specificity and functional avidity of a reconstructed TCR, which can be applied for monitoring antigen-specific T-cell responses, and potentially for guiding the design of effective T-cell-based immunotherapies.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30150207      PMCID: PMC6213317          DOI: 10.1182/blood-2018-04-843763

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

Review 1.  Hitting the Target: How T Cells Detect and Eliminate Tumors.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; Paul G Thomas
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Linking T-cell receptor sequence to functional phenotype at the single-cell level.

Authors:  Arnold Han; Jacob Glanville; Leo Hansmann; Mark M Davis
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

3.  A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.

Authors:  Eiji Kobayashi; Eishiro Mizukoshi; Hiroyuki Kishi; Tatsuhiko Ozawa; Hiroshi Hamana; Terumi Nagai; Hidetoshi Nakagawa; Aishun Jin; Shuichi Kaneko; Atsushi Muraguchi
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

Review 4.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

5.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Authors:  Jeffrey R Currier; Ellen G Kuta; Ellen Turk; Lyndsay B Earhart; Larry Loomis-Price; Sylvia Janetzki; Guido Ferrari; Deborah L Birx; Josephine H Cox
Journal:  J Immunol Methods       Date:  2002-02-01       Impact factor: 2.303

6.  Characterization of a new isoform of the NFAT (nuclear factor of activated T cells) gene family member NFATc.

Authors:  J Park; A Takeuchi; S Sharma
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

7.  Getting personal with neoantigen-based therapeutic cancer vaccines.

Authors:  Nir Hacohen; Edward F Fritsch; Todd A Carter; Eric S Lander; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

8.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

9.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

Review 10.  Functional avidity: a measure to predict the efficacy of effector T cells?

Authors:  Selena Viganò; Daniel T Utzschneider; Matthieu Perreau; Giuseppe Pantaleo; Dietmar Zehn; Alexandre Harari
Journal:  Clin Dev Immunol       Date:  2012-11-20
View more
  26 in total

Review 1.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 2.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis.

Authors:  Shuqiang Li; Jing Sun; Rosa Allesøe; Krishnalekha Datta; Yun Bao; Giacomo Oliveira; Juliet Forman; Roger Jin; Lars Rønn Olsen; Derin B Keskin; Sachet A Shukla; Catherine J Wu; Kenneth J Livak
Journal:  Nat Protoc       Date:  2019-07-24       Impact factor: 13.491

Review 4.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

5.  Landscape of helper and regulatory antitumour CD4+ T cells in melanoma.

Authors:  Giacomo Oliveira; Kari Stromhaug; Nicoletta Cieri; J Bryan Iorgulescu; Susan Klaeger; Jacquelyn O Wolff; Suzanna Rachimi; Vipheaviny Chea; Kate Krause; Samuel S Freeman; Wandi Zhang; Shuqiang Li; David A Braun; Donna Neuberg; Steven A Carr; Kenneth J Livak; Dennie T Frederick; Edward F Fritsch; Megan Wind-Rotolo; Nir Hacohen; Moshe Sade-Feldman; Charles H Yoon; Derin B Keskin; Patrick A Ott; Scott J Rodig; Genevieve M Boland; Catherine J Wu
Journal:  Nature       Date:  2022-05-04       Impact factor: 49.962

6.  Immortalization and functional screening of natively paired human T cell receptor repertoires.

Authors:  Ahmed S Fahad; Cheng-Yu Chung; Sheila N Lopez Acevedo; Nicoleen Boyle; Bharat Madan; Matias F Gutiérrez-González; Rodrigo Matus-Nicodemos; Amy D Laflin; Rukmini R Ladi; John Zhou; Jacy Wolfe; Sian Llewellyn-Lacey; Richard A Koup; Daniel C Douek; Henry H Balfour; David A Price; Brandon J DeKosky
Journal:  Protein Eng Des Sel       Date:  2022-02-17       Impact factor: 1.650

7.  Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.

Authors:  Zhuting Hu; Donna E Leet; Rosa L Allesøe; Giacomo Oliveira; Shuqiang Li; Adrienne M Luoma; Jinyan Liu; Juliet Forman; Teddy Huang; J Bryan Iorgulescu; Rebecca Holden; Siranush Sarkizova; Satyen H Gohil; Robert A Redd; Jing Sun; Liudmila Elagina; Anita Giobbie-Hurder; Wandi Zhang; Lauren Peter; Zoe Ciantra; Scott Rodig; Oriol Olive; Keerthi Shetty; Jason Pyrdol; Mohamed Uduman; Patrick C Lee; Pavan Bachireddy; Elizabeth I Buchbinder; Charles H Yoon; Donna Neuberg; Bradley L Pentelute; Nir Hacohen; Kenneth J Livak; Sachet A Shukla; Lars Rønn Olsen; Dan H Barouch; Kai W Wucherpfennig; Edward F Fritsch; Derin B Keskin; Catherine J Wu; Patrick A Ott
Journal:  Nat Med       Date:  2021-01-21       Impact factor: 53.440

Review 8.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

Review 9.  Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.

Authors:  Satyen H Gohil; J Bryan Iorgulescu; David A Braun; Derin B Keskin; Kenneth J Livak
Journal:  Nat Rev Clin Oncol       Date:  2020-12-04       Impact factor: 66.675

10.  Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.

Authors:  Giacomo Oliveira; Kari Stromhaug; Susan Klaeger; Tomasz Kula; Dennie T Frederick; Phuong M Le; Juliet Forman; Teddy Huang; Shuqiang Li; Wandi Zhang; Qikai Xu; Nicoletta Cieri; Karl R Clauser; Sachet A Shukla; Donna Neuberg; Sune Justesen; Gavin MacBeath; Steven A Carr; Edward F Fritsch; Nir Hacohen; Moshe Sade-Feldman; Kenneth J Livak; Genevieve M Boland; Patrick A Ott; Derin B Keskin; Catherine J Wu
Journal:  Nature       Date:  2021-07-21       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.